Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics

 
• By Lucie Ellis-Taitt

Merck & Co. has stealthily filed its highly anticipated Keytruda plus chemotherapy combination for first-line treatment of non-small cell lung cancer on the back of Phase II data, months earlier than expected and before the completion of a Phase III study.

Sparrow
Early bird Merck hopes to catch the worm, files Keytruda/Chemo combo months sooner than expected • Source: Shutterstock

More from Immuno-oncology

More from Anticancer